The FDA has approved nesiritide (Natrecor; Scios Inc, Sunnyvale, Calif) for initial intravenous treatment of patients with acutely decompensated congestive heart failure (ADCHF). The drug is a sterile, purified preparation containing the human B-type natriuretic peptide.
Nesiritide has been studied in 10 trials of patients with CHF, including the randomized Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial, which enrolled 489 patients requiring hospitalization for management of ADCHF with shortness of breath at rest.
Schwetz BA. Congestive Heart Failure Treatment. JAMA. 2001;286(13):1569. doi:10.1001/jama.286.13.1569-JFD10009-2-1